Company intelligence / Profile preview

Caribe Therapeutics

Ownership: Private
Employees: ~100
Development stage: Phase 3

Overview

Company has received FDA Study May Proceed letter for Phase 3 trial of intralesional rhEGF for diabetic foot ulcers. Also developing TASK-3 channel blockers with IC50 ~30μM in preclinical studies.

Modalities: Protein therapeuticsSmall moleculeProtein therapeuticsSmall molecule
Industry: Biotech

Drug pipeline

2 assets

rhEGF

Phase 3

Indications: Diabetic foot ulcers

1 more asset in the full pipeline.

Request access →

Partnerships

Center for Genetic Engineering and Biotechnology (CIGB) - CubaHarvard Medical SchoolMassachusetts Eye and Ear

Beyond the preview

Go deeper on Caribe Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Caribe Therapeutics.

Explore the full profile